Lyofal acquired by Synerlab (published : 15/11/2012)
SYNERLAB, a leading French pharmaceutical contract manufacturing firm, reinforces its leading market position on contract manufacturing market and take position into a fast growing market of lyophilized dry forms by acquiring Lyofal. SYNERLAB add competencies to its existing range of outsourcing pharmaceutical services.
SYNERLAB jointly announces the acquisitions of Lyofal and IDD-Tech Orleans, which specializes in the development of solid dosage forms. The expertise of IDD-Tech, which now becomes SYNERLAB Developpement, on galenic formulations as well as analytical drug development, will allow SYNERLAB to offer its clients a full range of services from the initial drug development to industrial scale production.
With these acquisitions, SYNERLAB reinforces its leading market position and becomes a company with five sites, employing 700 people and a turnover of € 85 million.
François Jerphagnon, Managing Director Small Market Enterprise Capital at AXA Private Equity declares: “With these acquisitions, SYNERLAB reinforces its leading position in contract manufacturing market. AXA Private Equity’s commitment alongside the management team over the last five years, including the closing of three build-up acquisitions, is a good example of how we bring value to our portfolio.”
For further information, go to www.synerlab.com